IGF-1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-25. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
=== International perspective === Rhodesia's Unilateral Declaration of Independence from the United Kingdom on 11 November 1965 was promptly condemned by the international community. The United Nations Security Council Resolution 216 of 12 November 1965 called "upon all States not to recognise this illegal racist minority regime in Southern Rhodesia." Rhodesia campaigned for international acceptance and invoked the doctrine of non-intervention in internal affairs as justification for rebuking external criticism of its internal policies. However, the emerging doctrine of self-determination in colonial situations meant that most nations regarded Rhodesia's self-declared independence as illegitimate. Zambia, formerly Northern Rhodesia, took a pragmatic approach towards Rhodesia. Kenneth Kaunda, heavily dependent on access through Rhodesia for his nation's copper ore exports, fuel, and power imports unofficially worked with the Rhodesian government. Rhodesia still allowed Zambia to export and import its goods through its territory to Mozambique ports, despite the Zambian government's official policy of hostility and non-recognition of the post-UDI Smith Administration. The United States, like all other Western nations, refused to recognise Rhodesia, but unlike others allowed its Consulate-General to function as a communications conduit between the US government in Washington, DC and the Rhodesian government in Salisbury. When Rhodesia set up the Rhodesian Information Office in Washington, DC, OAS nations loudly protested.
Enterocytes, or intestinal absorptive cells, are simple columnar epithelial cells which line the inner surface of the small and large intestines. A glycocalyx surface coat contains digestive enzymes. Microvilli on the apical surface increase its surface area. This facilitates transport of numerous small molecules into the enterocyte from the intestinal lumen. These include broken down proteins, fats, and sugars, as well as water, electrolytes, vitamins, and bile salts. Enterocytes also have an endocrine role, secreting hormones such as leptin.
== Defunct == Beefsteak Charlie's Bikinis Sports Bar & Grill Bill Knapp's Bugaboo Creek Steakhouse Burger Chef Camille's Sidewalk Cafe Carrows Restaurants Cheeseburger in Paradise Chi Chi's Chicken in the Rough Druther's ESPN Zone Fresh Choice Furr's Good Earth Hamburger Hamlet Henry's Hamburgers Horne's Hot 'n Now K&W Cafeterias Koo Koo Roo Lone Star Steakhouse & Saloon Lyon's Morrison's Cafeteria Naugles On the Border Mexican Grill & Cantina Pizza Fusion Royal Castle Red Barn Sambo's ShopHouse Southeast Asian Kitchen Smokey Bones ShowBiz Pizza Place Steak and Ale Sweet Tomatoes/Souplantation Trump Burger Yogi Bear's Honey Fried Chicken York Steak House Zoës Kitchen
The homeostatic mechanism which controls the plasma sodium concentration is rather more complex than most of the other homeostatic mechanisms described on this page. The sensor is situated in the juxtaglomerular apparatus of kidneys, which senses the plasma sodium concentration in a surprisingly indirect manner. Instead of measuring it directly in the blood flowing past the juxtaglomerular cells, these cells respond to the sodium concentration in the renal tubular fluid after it has already undergone a certain amount of modification in the proximal convoluted tubule and loop of Henle. These cells also respond to rate of blood flow through the juxtaglomerular apparatus, which, under normal circumstances, is directly proportional to the arterial blood pressure, making this tissue an ancillary arterial blood pressure sensor. In response to a lowering of the plasma sodium concentration, or to a fall in the arterial blood pressure, the juxtaglomerular cells release renin into the blood. Renin is an enzyme which cleaves a decapeptide (a short protein chain, 10 amino acids long) from a plasma α-2-globulin called angiotensinogen. This decapeptide is known as angiotensin I. It has no known biological activity. However, when the blood circulates through the lungs a pulmonary capillary endothelial enzyme called angiotensin-converting enzyme (ACE) cleaves a further two amino acids from angiotensin I to form an octapeptide known as angiotensin II. Angiotensin II is a hormone which acts on the adrenal cortex, causing the release into the blood of the steroid hormone, aldosterone.
Sources: en.wikipedia.org
== Names == The adjective Müllerian is written either Müllerian or müllerian, depending on the governing style guide; the derived term with the prefix anti- is then anti-Müllerian, anti-müllerian, or antimüllerian. The Müllerian ducts are named after Johannes Peter Müller. A list of the names that have been used for the antimüllerian hormone is as follows. For the sake of simplicity, this list ignores some orthographic variations; for example, it gives only one row for "Müllerian-inhibiting hormone", although there are four acceptable stylings thereof (capital M or lowercase m, hyphen or space).
Papaverine was discovered in 1848 by Georg Merck (1825–1873). Merck was a student of the German chemists Justus von Liebig and August Hofmann, and he was the son of Emanuel Merck (1794–1855), founder of the Merck corporation, a major German chemical and pharmaceutical company.
September 21: Malta becomes independent from the UK. September 24: The Mozambican War of Independence begins in Portuguese Mozambique. October 12: The first spaceflight to carry multiple crewman into orbit was conducted by Voskhod 1. October 14: Leonid Brezhnev succeeds Khrushchev to become General Secretary of the Communist Party of the Soviet Union, with Alexei Kosygin as his Premier. October 16: China tests its first atomic bomb. The test makes China the world's fifth nuclear power. October 24: Northern Rhodesia renamed Zambia becomes independent from the UK. November 28: Mariner 4 was launched.
Heinrich Geissler invented the mercury displacement pump in 1855 and achieved a record vacuum of about 10 Pa (0.1 Torr). A number of electrical properties become observable at this vacuum level, and this renewed interest in vacuum. This, in turn, led to the development of the vacuum tube. The Sprengel pump was a widely used vacuum producer of this time.
DszB, the final enzyme in the pathway, is also one of the slowest with a turnover rate of 1.7 ± 0.2 min−1, becoming a major bottleneck of the 4S pathway. A computational rational design approach determined a set of mutations that could accelerate the charge transfer occurring in the active site during DszB reaction mechanism, reducing the activation energy for the reaction and potentially increasing its turnover rate. DszB's catalytic efficiency and thermostability was also addressed in an experimental mutagenesis approach, the Y63F/Q65H double mutant revealed an increase in the enzyme's thermostability without loss of catalytic efficiency. DszD has also been targeted for rate enhancing mutation on the Thr62 residue. Mutation of Thr62 by Asn and Ala residues managed to increase its activity 5- and 7-fold, respectively. A computational study demonstrated that substitutions in position 62 of DszD sequence have a major impact in the activation energy for the hydride transfer reaction from NADH to FAD. The Thr62 mutation by an Asp residue returns the lowest activation energy from all possible mutants at this position due to the stabilization effect induced by Asp negative charge.
Sources: en.wikipedia.org
In Tulsa, Jolene finds work as a receptionist and banquet server. She meets Brad Benton, the son of a wealthy family. He relentlessly pursues her, sending flowers to her workplace and charming her into dates. Outwardly religious but obnoxiously arrogant, he is rude, entitled, narcissistic and demanding to everyone. Brad pressures Jolene into quickly getting married and on their wedding night, he discovers a tattoo of a heart with flames on her backside, this triggers him and he anally rapes her. When Jolene becomes pregnant, Brad interrogates her on how many people she has had sex with; when she refuses to comply, he slaps her across the face. After their baby is born, Brad's parents investigate Jolene's past and inform him. He then brutally attacks her, permanently damaging her vocal cords. She tries to leave and take Brad Jr., but a domestic violence lawyer refuses to take her case due to her past. While staying in a shelter for battered women, the police come and arrest Jolene for kidnapping and Brad is granted an annulment. Jolene is convicted of the kidnapping and is allowed supervised visits. She decides to exit her baby's life while he is an infant, reasoning that he can imagine his mother to be anybody. Finally, Jolene ends up in Los Angeles, working as a comic illustrator for a graphic novel company, where she incorporates events from her life into her work. In her final narration, she reveals that she has dreams to be an actress and that a film studio might want to use her.
== Animal studies == Meso-zeaxanthin has been tested for animal toxicity by several research teams, who report a lack of toxicity. The NOAEL ('No Observed-Adverse-Effect Level') of meso-zeaxanthin is far greater than doses used in dietary supplements. In 2016, the GRAS ('Generally Regarded As Safe') status of meso-zeaxanthin was acknowledged by the FDA.[1]
== Total synthesis == Due to the high potency and clinical need for cancer treatments, epothilones have been the target of many total syntheses. The first group to publish the total synthesis of epothilones was S. J. Danishefsky et al. in 1996. This total synthesis of epothilone A was achieved via an intramolecular ester enolate-aldehyde condensation. Other syntheses of epothilones have been published by Nicolaou, Schinzer, Mulzer, and Carreira. In this approach, key building blocks aldehyde, glycidols, and ketoacid were constructed and coupled to the olefin metathesis precursor via an aldol reaction and then an esterification coupling. Grubbs' catalyst was employed to close the bis terminal olefin of the precursor compound. The resulting compounds were cis- and trans-macrocyclic isomers with distinct stereocenters. Epoxidation of cis- and trans-olefins yield epothilone A and its analogs. One of the total syntheses of epothilone B is outlined below and was described by the laboratory of K. C. Nicolaou. The retrosynthetic analysis revealed 1, 2, and 3 as the building blocks (Figure 1).
Serine hydroxymethyltransferase (SHMT) also catalyzes the biosynthesis of glycine (retro-aldol cleavage) from serine, transferring the resulting formaldehyde synthon to 5,6,7,8-tetrahydrofolate. However, that reaction is reversible, and will convert excess glycine to serine. SHMT is a pyridoxal phosphate (PLP) dependent enzyme.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.